When was Strand Therapeutics founded?

Strand Therapeutics was founded in 2017 and raised its 1st funding round 2 years after it was founded.

Where is Strand Therapeutics located?

Strand Therapeutics is headquartered in Cambridge, United States. It is registered at Alexandria Launchlabs One Kendall Square, Bldg 200 Suite 001 Cambridge, MA 02139 USA.

Who is the current CEO of Strand Therapeutics?

Jake Becraft of Strand Therapeutics.

How many employees does Strand Therapeutics have?

As of Jun 30, 2026, the latest employee count at Strand Therapeutics is 124.

Is Strand Therapeutics a funded company?

Strand Therapeutics is a funded company, having raised a total of $256M across 7 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on May 19, 2019.

How much is Strand Therapeutics worth?

The latest valuation of Strand Therapeutics is $***** as of Aug 07, 2025.

When was the latest funding round of Strand Therapeutics?

Strand Therapeutics' latest funding was a $***** Series B round on May 23, 2025, with participation from 13 investors.

Where does Strand Therapeutics rank among its competitors?

Strand Therapeutics ranks 18th amongst 2885 active competitors, of which 1015 are funded. It stands 4th in terms of total funding among its competitors. The most recent competitor to raise funding was Karyopharm, which secured $30M in Mar, 2026.

Who are the top competitors of Strand Therapeutics?

Strand Therapeutics' top competitors include Jazz Pharmaceuticals, Alnylam and Sana Biotechnology. Among them, Karyopharm secured the most recent funding round in March, 2026.

Strand Therapeutics - 2026 Company Profile, Team, Funding & Competitors

Company Details

Provider of a platform to deliver mRNA therapeutics for multi-functional treatments. The programming platform detects the location and enhances the cell type protein expression in the patient's body to optimize the immunotherapy treatments.

Website: www.strandtx.com/
Social
Email ID: *****@strandtx.com
Registered Address: Alexandria Launchlabs One Kendall Square, Bldg 200 Suite 001 Cambridge, MA 02139 USA

Key Metrics

Founded Year

2017

Location

Cambridge, United States

Stage

Series B

Total Funding

$256M in 7 rounds

Latest Funding Round

Series B, May 23, 2025, $*****

Post Money Valuation

$***** as on Aug 07, 2025

Investors

MassChallenge & 20 more

Ranked

18^th among 2885 active competitors

Employee Count

124 as on Jun 30, 2026

Similar Companies

Alnylam & 715 more

View Strand Therapeutics' full profile

Strand Therapeutics is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Strand Therapeutics Inc CIN: 82-4027324 , United States, Active	Dec 31, 2016	-	47 (As on Dec 31, 2021)	-

Strand Therapeutics has raised a total funding of $256M over 7 rounds. Its first funding round was on May 19, 2019. Its latest funding round was a Series B round on May 23, 2025 for $*****. 13 investors participated in its latest round. Strand Therapeutics has 21 institutional investors.

Here is the list of recent funding rounds of Strand Therapeutics:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
May 23, 2025	1513973	Series B	1024340	8031857	6417140	7066520
Nov 28, 2022	6287984	Series A	3206952	9992927	3365765	Lilly & 2 more
Jun 23, 2021	6173859	Series A	6909738	7539218	9873621	Redmile Group & 4 more

Access funding benchmarks and valuations. Sign up today!

View details of Strand Therapeutics's funding rounds and investors

The founders of Strand Therapeutics are Darrell Irvine, Jake Becraft, Ron Weiss and Tasuku Kitada.

Here are the details of Strand Therapeutics' key team members:

Darrell Irvine: Co-Founder of Strand Therapeutics and founder of 2 other companies, Ankyra and Elicio.
Contact Info: 1 email address
Jake Becraft: Co-Founder & CEO of Strand Therapeutics.
Ron Weiss: Co-Founder of Strand Therapeutics.
Tasuku Kitada: Co-founder, Board Director, President, and Head of R&D of Strand Therapeutics.

View details of Strand Therapeutics's Founder profiles and Board Members

Strand Therapeutics' employee count trend

Strand Therapeutics has 124 employees as of Jun 26. Here is Strand Therapeutics's employee count trend over the years:

Employee count trend for Strand Therapeutics

Uncover Strand Therapeutics' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Strand Therapeutics include Jazz Pharmaceuticals, Alnylam and Sana Biotechnology. Here is the list of Top 10 competitors of Strand Therapeutics, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	82/100
2nd	Alnylam 2002, Cambridge (United States), Public	Developer of RNA interference-based therapeutics for multiple disorders	$17M	Military Health, BB Biotech & 13 others	79/100
3rd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Baillie Gifford, Altitude Life Science Ventures ... & 17 others	75/100
4th	Spark Therapeutics 2013, Philadelphia (United States), Acquired	Developer of gene therapy for rare diseases	$82.8M	Sofinnova Investments, T. Rowe Price & 6 others	73/100
5th	Blueprint Medicines 2008, Cambridge (United States), Acquired	Developer of selective kinase inhibitors for patients with genomically defined cancers	$115M	Nextech Invest, Third Rock Ventures & 20 others	72/100
6th	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	BVF Partners, Driehaus & 15 others	72/100
7th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, SV Health Investors & 17 others	72/100
8th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Delos Capital Partners, Pappas Capital & 19 others	72/100
9th	Moderna 2010, Cambridge (United States), Public	Developer of mRNA-based therapeutics for a wide range of diseases	$2.78B	AstraZeneca, HHS & 32 others	71/100
10th	Karyopharm 2008, Newton (United States), Public	Biopharmaceutical company focused on developing and commercializing innovative cancer therapies	$98.4M	Foresite Capital, Avidity Partners & 16 others	71/100
18th	Strand Therapeutics 2017, Cambridge (United States), Series B	Provider of platform to deliver mRNA therapeutics for multi functional treatments	$256M	Kinnevik, Redmile Group & 19 others	70/100

Get insights and benchmarks for competitors of 2M+ companies! Sign up today!

Looking for more details on Strand Therapeutics's competitors? Click here to see the top ones

Strand Therapeutics has made no investments or acquisitions yet.

Media has covered Strand Therapeutics for a total of 8 events in the last 1 year, 4 of them have been about people movement and 1 about company updates.